Skip Ribbon Commands
Skip to main content

News

 

 

Terumo Group Establishes "Terumo Group Sustainability Policy" and Revises the Sustainability Prioritieshttps://www.terumo-europe.com/en-emea/news/terumo-group-establishes-"terumo-group-sustainability-policy"-and-revises-the-sustainability-prioritiesTerumo Group Establishes "Terumo Group Sustainability Policy" and Revises the Sustainability PrioritiesTOKYO, JAPAN12/19/2021 11:00:00 PM<h4>To realize “Advancement of Healthcare” and “Enhancement of Patients’ QOL”<br></h4>
Terumo Announces 5-Year Growth Strategy (GS26) to Deliver Solutions to 21st Century Healthcare Challengeshttps://www.terumo-europe.com/en-emea/news/terumo-announces-5-year-growth-strategy-(gs26)-to-deliver-solutions-to-21st-century-healthcare-challengesTerumo Announces 5-Year Growth Strategy (GS26) to Deliver Solutions to 21st Century Healthcare ChallengesTOKYO, JAPAN12/15/2021 11:00:00 PM<h4 style="text-align:justify;">​Terumo Corporation (TSE: 4543) today announced its new 5-Year Growth strategy (GS26*1) for the fiscal year 2022 to 2026 (April 1, 2022 to March 31, 2027). <br></h4>
Terumo Corporation and Diabeloop SA. Enter into Comprehensive Strategic Partnership Agreement to Expand Their Diabetes Care Offeringhttps://www.terumo-europe.com/en-emea/news/terumo-corporation-and-diabeloop-sa-enter-into-comprehensive-strategic-partnership-agreement-to-expand-their-diabetes-careTerumo Corporation and Diabeloop SA. Enter into Comprehensive Strategic Partnership Agreement to Expand Their Diabetes Care OfferingTOKYO, JAPAN and PARIS, FRANCE11/16/2021 11:00:00 PM<h4 style="text-align:justify;">​Terumo Corporation, a global leader in medical technology and the French company Diabeloop, a pioneer in therapeutic AI, announced today that they have signed an agreement for a comprehensive strategic partnership. With this agreement, in addition to the current joint development of the AID system for Japan, they will work closely to bring Automated Insulin Delivery solutions to Europe with potential further global expansion.<br><br></h4>
Terumo to Develop Smartphone-type Device to Control Insulin Pumphttps://www.terumo-europe.com/en-emea/news/terumo-to-develop-smartphone-type-device-to-control-insulin-pumpTerumo to Develop Smartphone-type Device to Control Insulin PumpTOKYO, JAPAN11/7/2021 11:00:00 PM<h4 style="text-align:justify;">​Terumo Corporation (TSE: 4543) today announced that it has partnered with an European company to co-develop a new technology to enable MEDISAFE WITH insulin patch pump to be controlled by a smartphone-type device. With this upgrade, Terumo aims to enhance the operability of MEDISAFE WITH as well as allowing insulin pump therapy to be harmonized into the day-to-day life of people with diabetes. The smartphone-type device will be dedicated to controlling the MEDISAFE WITH.</h4><h4><br></h4>
Terumo Celebrates 100th Anniversary of Contributing to Society Through Healthcarehttps://www.terumo-europe.com/en-emea/news/terumo-celebrates-100th-anniversary-of-contributing-to-society-through-healthcareTerumo Celebrates 100th Anniversary of Contributing to Society Through HealthcareTOKYO, JAPAN9/16/2021 10:00:00 PM<p>​Terumo Corporation (TSE: 4543), a global leader in medical technology, today celebrates its 100th anniversary. The company, based in Tokyo, boasts over 25,000 associates worldwide, providing products and services to more than 160 countries and regions across the globe. <br></p>